AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AHA Meta-comments
II. ISCHEMIA-Extended
- ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up https://www.medscape.com/viewarticle/983657
- Survival After Invasive or Conservative Management of Stable Coronary Disease https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062714
III. STRONG-HF
- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870
- STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1
IV. DCP
- Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP https://www.medscape.com/viewarticle/983608
- HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science https://www.medscape.com/viewarticle/983614
V. TRANSFORM HF
- No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF https://www.medscape.com/viewarticle/983611
VI. PROMINENT
- Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial https://www.medscape.com/viewarticle/983610
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2210645
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net